IP Verse

Compound For Use In The Treatment Of Ocular Disorders - EP3811943

The patent EP3811943 was granted to Aerie Pharmaceuticals on Feb 22, 2023. The application was originally filed on Mar 14, 2014 under application number EP20207657A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3811943

AERIE PHARMACEUTICALS
Application Number
EP20207657A
Filing Date
Mar 14, 2014
Status
Granted And Under Opposition
Jan 20, 2023
Publication Date
Feb 22, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKNov 22, 2023RUSSELLADMISSIBLE
ISARPATENT PATENT UND RECHTSANWALTE BARTH HASSA PECKMANN UND PARTNER MBBNov 22, 2023ISARPATENTADMISSIBLE
TER MEER STEINMEISTER & PARTNER PATENTANWALTE MBBNov 22, 2023TER MEER STEINMEISTER & PARTNERADMISSIBLE

Patent Citations (40) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS2009186917
DESCRIPTIONUS5770759
DESCRIPTIONUS5889052
DESCRIPTIONUS5977173
DESCRIPTIONUS5994397
DESCRIPTIONUS6025392
DESCRIPTIONUS6030999
DESCRIPTIONUS6037364
DESCRIPTIONUS6037368
DESCRIPTIONUS6048895
DESCRIPTIONWO0003736
DESCRIPTIONWO0003980
DESCRIPTIONWO9519964
DESCRIPTIONWO9610407
DESCRIPTIONWO9723223
DESCRIPTIONWO9812175
DESCRIPTIONWO9820880
DESCRIPTIONWO9820881
DESCRIPTIONWO9821180
DESCRIPTIONWO9821181
DESCRIPTIONWO9821182
DESCRIPTIONWO9839293
DESCRIPTIONWO9850024
DESCRIPTIONWO9857930
DESCRIPTIONWO9857942
DESCRIPTIONWO9902165
DESCRIPTIONWO9912895
DESCRIPTIONWO9912896
DESCRIPTIONWO9912898
DESCRIPTIONWO9925358
DESCRIPTIONWO9926629
DESCRIPTIONWO9932441
OPPOSITIONUS8394826
OPPOSITIONWO2010126626
OPPOSITIONWO2014144781
SEARCHEP1541151
SEARCHEP2671586
SEARCHWO2010011853
SEARCHWO2010127329
SEARCHWO2012105674

Non-Patent Literature (NPL) Citations (27) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- BERGE et al., "Pharmaceutically Acceptable Salts", J. Pharm. Sci., (19770000), vol. 66, pages 1 - 19
DESCRIPTION- C.T.F.A. Cosmetic Ingredient Handbook, (19920000), pages 587 - 592
DESCRIPTION- "Derivatives of 17-Phenyl-18,19,20-trinorprostaglandin F Isopropyl Ester: Potential Anti-glaucoma Agents", C. LILJEBRISG. SELENB. RESULJ. STERNSCHANTZU. HACKSELL, Journal of Medicinal Chemist, (19950000), vol. 38, pages 289 - 304
DESCRIPTION- Journal of Organic Chemistry
DESCRIPTION- MCCUTCHEON'S, Emulsifiers & Detergents, North American Edition, (19940000), vol. 1, pages 236 - 239
DESCRIPTION- "Periodic Table of the Elements", Handbook of Chemistry and Physics
DESCRIPTION- Remington's Pharmaceutical Sciences, Meade Publishing Co., (19750000), pages 335 - 337
OPPOSITION- Anonymous, "RHOPRESSA (netarsudil ophthalmic solution) Label, NDA 208254, Reference ID:4194833", NDA 208254, (20171201), no. ID: 4194833, XP055612923
OPPOSITION- Anonymous, "Study of AR-13324 in Patients With Elevated Intraocular Pressure", ClinicalTrials.gov; NCT01528787, (20120718), ClinicalTrials.gov; NCT01528787, URL: https://classic.clinicaltrials.gov/ct2/history/NCT01528787?V_7=View#StudyPageTop, (20240321), XP093143985
OPPOSITION- Casey Kopczynski; Cheng-Wen Lin; Mitchell deLong; Jeffrey Yingling; Geoff Heintzelman; Jill Sturdivant; Bryan Sherman; Carmen Laethem; Thomas van Haarlem, "IOP-lowering Efficacy And Tolerability Of AR-13324, A Dual Mechanism Kinase Inhibitor For The Treatment Of Glaucoma", Investigative Ophthalmology & Visual Science, Association for Research in Vision and Ophthalmology, US, US , (20120301), vol. 53, no. 14, ISSN 0146-0404, page 5080, XP009553501
OPPOSITION- Deupree Susan M, Goodman Kelli D, Delong Mitchell A, "LC/MS/MS Methodology for Quantification of AR-13323, AR-13324, AR-13503, and AR-13534 in Rabbit and Monkey Plasma ", Conference Poster presented at AAPSAt, (20120101), XP093143972
OPPOSITION- Kumar L; Amin A; Bansal A K, "Salt selection in drug development", Pharmaceutical Technology, ADVANSTAR COMMUNICATIONS,INC., US, US , (20080301), vol. 32, no. 3, ISSN 1543-2521, pages 128 - 146, XP008127365
OPPOSITION- Mitchell A. deLong, Jeff Yingling, Cheng-Wen Lin, Bryan Sherman, Jill Sturdivant, Geoff Heintzelman, Carmen Lathem, Tom van Haarlem, Casey Kopczynski, "Discovery and SAR of a Class of Ocularly-active Compounds Displaying a Dual Mechanism of Activity for the Treatment of Glaucoma", ARVO Annual Meeting, May 6 - 10 2012, Fort Lauderdale, FL, (20120506), page 1, XP002725387
OPPOSITION- P. Heinrich Stahl; Camille G. Wermuth, "Introduction", P. Heinrich Stahl; Camille G. Wermuth, STAHL ET AL. (ED.), Handbook of Pharmaceutical Salts, Weinheim , WILEY-VCH , (20020101), pages 1 - 7, ISBN 3-906390-26-8, XP009553026
OPPOSITION- Song H; Gao D, "Fasudil, a Rho-associated protein kinase inhibitor, attenuates retinal ischemia and reperfusion injury in rats", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, Spandidos Publications, GR, GR , (20110801), vol. 28, no. 2, ISSN 1107-3756, pages 193 - 198, XP009189261
OPPOSITION- Stahl P. Heinrich, Camille G. Wermuth, "3. The Salt-Optimization Process - First Phase", Handbook of Pharmaceutical Salts. Properties, Selection, and Use. , VHCA and WILEY-VCH, (20020101), pages 167 - 173, 216-217, XP093145672
OPPOSITION- David P. Elder, Ed Delaney, Andrew Teasdale, Steve Eyley, Van D. Reif, Karine Jacq, Kevin L. Facchine, Rolf Schulte Oestrich, Patrick Sandra, Frank David, "The utility of sulfonate salts in drug development", Journal of Pharmaceutical Sciences, American Chemical Society and American Pharmaceutical Association, US, US , (20100101), vol. 99, no. 7, doi:10.1002/jps.22058, ISSN 0022-3549, pages 2948 - 2961, XP055091305
OPPOSITION- BERGE S. M., BIGHLEY L. D., MONKHOUSE D. C., "Pharmaceutical Salts", Journal of Pharmaceutical Sciences, American Chemical Society and American Pharmaceutical Association, US, US , (19770101), vol. 66., no. 01., doi:10.1002/jps.2600660104, ISSN 0022-3549, pages 01 - 19., XP000562636
OPPOSITION- Gould, P.L., "Salt selection for basic drugs", International Journal of Pharmaceutics, ELSEVIER, NL, NL , (19861101), vol. 33, no. 1-3, doi:10.1016/0378-5173(86)90055-4, ISSN 0378-5173, pages 201 - 217, XP025813036
OPPOSITION- G Steffen Paulekuhn, Jennifer B Dressman and Christoph Saal, "Trends in Active Pharmaceutical Ingredient Salt Selection based on Analysis of the Orange Book Database", Journal of Medicinal Chemistry, American Chemical Society, US, US , (20071227), vol. 50, no. 26, doi:10.1021/jm701032y, ISSN 0022-2623, pages 6665 - 6672, XP002651069
OPPOSITION- Richard Bastin, "Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities", Organic Process Research & Development, (2000), vol. 4, doi:10.1021/op000018u, XP008154792
OPPOSITION- Richard J. Bastin, Michael J. Bowker, and Bryan J. Slater, "Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities", Organic Process Research & Development, American Chemical Society, US, US , (20000719), vol. 4, no. 5, doi:10.1021/op000018u, ISSN 1083-6160, pages 427 - 435, XP008154792
OPPOSITION- Pawar Pravin, Katara Rajesh, Mishra Sushil, Majumdar Dipak K, "Topical ocular delivery of fluoroquinolones", Expert Opinion on Drug Delivery, Informa Healthcare, GB, GB , (20130501), vol. 10, no. 5, doi:10.1517/17425247.2013.772977, ISSN 1742-5247, pages 691 - 711, XP093144009
OPPOSITION- Bhartiya Shibal, Parul Ichhpujani, "The Need to maintain Intraocular Pressure over 24 Hours", Journal of Current Glaucoma Practice, (20121201), vol. 6, no. 3, doi:10.5005/jp-journals-10008-1118, ISSN 0974-0333, pages 120 - 123, XP093143980
SEARCH- Anonymous, "Aerie Pharmaceuticals, Inc. Gets Good News on Glaucoma Treatment", (20120211), Internet, URL: http://www.biospace.com, (20140603), XP002725385 [A] 1-11 * 4th paragraph *
SEARCH- Anonymous, "Bright New Ideas in Glaucoma Treatment", (201301), Internet, URL: http://mydigimag.rrd.com, (20140603), XP002725386 [A] 1-11 * page 1, paragraph 5 *
SEARCH- Anonymous, "Discovery and SAR of a Class of Ocularly-active Compounds Displaying a Dual Mechanism of Activity for the Treatment of Glaucoma", ARVO Annual Meeting, May 6 - 10 2012, Fort Lauderdale, FL, (20120506), Internet, URL: http://www.aeriepharma.com, (20140603), XP002725387 [A] 1-11 * abstract *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents